Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Alzheimer's Screening and Prevention Act of 2025 (ASAP Act) would require Medicare to cover blood-based tests that detect early signs of Alzheimer's disease and related dementias, even before symptoms appear. The bill applies to seniors enrolled in Medicare and would make these screening tests available starting January 1, 2028. The tests covered would include blood tests analyzing cell-free nucleic acids, genomic sequencing, protein expression, and other FDA-approved equivalent tests designed to identify early-stage disease. The legislation does not specify dedicated funding amounts but directs Medicare to cover and pay for these tests once they are FDA-cleared or approved. This change aims to enable earlier diagnosis and potential intervention for dementia patients while the disease is in its earliest stages.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.